A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

2025-523819-11-00 · tracked via the Priya Life Science EU tracker

Sponsor

AbbVie Deutschland GmbH & Co. KG

Sponsor type

Pharmaceutical company

Therapeutic area

Neoplasms

Decision date

27/07/2026

Enrollment target

125

Sites

Italy, Greece, Spain, Belgium, France, Austria, Germany

Condition studied

Small Cell Lung Cancer

Investigational medicinal product(s)

TOPOTECANTOPOTECANTOPOTECANABBV-706

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Primary endpoint

Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR), Overall Survival (OS)

Endpoint detail

Progression-free survival (PFS) based on BICR assessment per RECIST v1.1., Duration of response (DoR) based on BICR assessment per RECIST v1.1., Change from baseline at Week 12 in physical functioning as measured by the physicalfunctioning domain of the EORTC QLQ-C30., Change from baseline at Week 12 in Global Health Status (GHS)/Quality of life (QoL) as measured by the EORTC QLQ-C30 GHS/QoL scale

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523819-11-00 on CTIS ↗ ← All trials in the EU